Back to search results

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

IsraelRecruitingPHASE1

Conditions

Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer · HR+/HER2- Ductal and Lobular Breast Cancer · Triple Negative Breast Cancer · Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Uni of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Sebastian Eady) · smeady@uabmc.edu
    Contact: Principal Investigator (Jonathan McConathy)

  • University of California LA, Los Angeles, California, United States

    Contact: Study coordinator (Angela Lool) · alool@mednet.ucla.edu
    Contact: Principal Investigator (Jonathan W Goldman)

  • Stanford University Medical Center, Palo Alto, California, United States

    Contact: Study coordinator (Maria Isabel Leonio) · ileonio@stanford.edu
    Contact: Principal Investigator (Farshad Moradi)

  • Mayo Clinic Jacksonville, Jacksonville, Florida, United States

    Contact: Study coordinator (Alberta Lalljie) · Lalljie.Albertha@mayo.edu · 904-953-7648
    Contact: Principal Investigator (Ephraim Parent)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Jonathan Robert Kim) · jkim215@mgh.harvard.edu
    Contact: Principal Investigator (Shadi Abdar Esfahani)

  • BAMF Health, Grand Rapids, Michigan, United States

    Study coordinator · researchclinicalteam@bamfhealth.com
    Contact: Principal Investigator (Brandon Mancini)

  • BAMF Health, Grand Rapids, Michigan, United States

    Contact: Study coordinator (Lisa Orange) · lisa.orange@bamfhealth.com
    Contact: Principal Investigator (Brandon Mancini)

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Lucas Hamann) · hamann.lucas@mayo.edu · 507-538-2155
    Contact: Principal Investigator (Andrea Wahner Hendrickson)

  • Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States

    Contact: Study coordinator (Denisse Harkins) · dvelazquez1@mdanderson.org · 713-792-2921
    Contact: Principal Investigator (Jordi Rodon)

  • University Of Washington, Seattle, Washington, United States

    Contact: Study coordinator (Heather White) · hwhite@fredhutch.org
    Contact: Principal Investigator (Amir Iravani)

  • Novartis Investigative Site, Brussels, Belgium

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Bron, France

  • Novartis Investigative Site, Villejuif, France

  • Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, München, Germany

  • Novartis Investigative Site, Rostock, Germany

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Reggio Emilia, RE, Italy

  • Novartis Investigative Site, Nijmegen, Gelderland, Netherlands

  • Novartis Investigative Site, Utrecht, Netherlands

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Geneva, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)